Retrospective, multi-centre, open-label study on the use of alemtuzumab for relapsing–remitting multiple sclerosis in clinical practice: A 4-year follow-up

Retrospective, multi-centre, open-label study on the use of alemtuzumab for relapsing–remitting multiple sclerosis in clinical practice: A 4-year follow-up

Introduction: The efficacy and safety of alemtuzumab for patients with relapsing–remitting multiple sclerosis (RRMS) have been demonstrated in clinical trials. However, due to the limitations of these studies, it is important to assess the effects of the drug in clinical practice. The purpose of thi...

Full description

Saved in:
Bibliographic Details
Main Authors: A. Pato-Pato, P. Gabeiras-Araujo, M. Lorenzo-García, C. Hernandez-Cerón, J.R. Lorenzo-González, D.A. García-Estévez
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Neurology Perspectives
Subjects:
Alemtuzumab
Mutiple sclerosis
Observational study
Effectiveness
Online Access:http://www.sciencedirect.com/science/article/pii/S2667049625000109
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items